Product Details
| Product Name:
Glenzocimab |
CAS No.:
2101829-58-5 |
| Purity:
100% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2026/05/21 |
Product Introduction
Bioactivity
| Name | Glenzocimab |
| Description | Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis. |
| In vitro | Inhibited the binding of GPVI-Fc to collagen immobilized on microtiter plates, glenzocimab (0-100,000 ng/mL) demonstrated an IC50 of 1.37 μg/mL[2]. |
| In vivo | Glenzocimab ( 1-8 mg / kg ; i.v. ) inhibited collagen-induced platelet aggregation in cynomolgus monkeys [ 2 ]. |
| Storage | Store at low temperature
-20°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Glenzocimab | ACT-017 | ACT 017 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States